Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry.


Journal

The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 13 12 2018
medline: 14 1 2020
entrez: 13 12 2018
Statut: ppublish

Résumé

Surveillance programs on high-risk individuals (HRIs) can detect pre-malignant lesions or early pancreatic cancer (PC). We report the results of the first screening round of the Italian multicenter program supported by the Italian Association for the study of the Pancreas (AISP). The multicenter surveillance program included asymptomatic HRIs with familial (FPC) or genetic frailty (GS: BRCA1/2, p16/CDKN2A, STK11/LKB1or PRSS1, mutated genes) predisposition to PC. The surveillance program included at least an annual magnetic resonance cholangio pancreatography (MRCP). Endoscopic ultrasound (EUS) was proposed to patients who refused or could not be submitted to MRCP. One-hundreds eighty-seven HRIs underwent a first-round screening examination with MRCP (174; 93.1%) or EUS (13; 6.9%) from September 2015 to March 2018.The mean age was 51 years (range 21-80).One-hundreds sixty-five (88.2%) FPC and 22 (11.8%) GF HRIs were included. MRCP detected 28 (14.9%) presumed branch-duct intraductal papillary mucinous neoplasms (IPMN), 1 invasive carcinoma/IPMN and one low-grade mixed-type IPMN, respectively. EUS detected 4 PC (2.1%): 1 was resected, 1 was found locally advanced intraoperatively, and 2 were metastatic. Age > 50 (OR 3.3, 95%CI 1.4-8), smoking habit (OR 2.8, 95%CI 1.1-7.5), and having > 2 relatives with PC (OR 2.7, 95%CI 1.1-6.4) were independently associated with detection of pre-malignant and malignant lesions. The diagnostic yield for MRCP/EUS was 24% for cystic lesions. The overall rate of surgery was 2.6% with nil mortality. The rate of malignancies found in this cohort was high (2.6%). According to the International Cancer of the Pancreas Screening Consortium the screening goal achievement was high (1%).

Identifiants

pubmed: 30538291
doi: 10.1038/s41395-018-0414-z
pii: 10.1038/s41395-018-0414-z
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

665-670

Commentaires et corrections

Type : CommentIn

Auteurs

Salvatore Paiella (S)

General and Pancreatic Surgery Department, Pancreas Institute, University of Verona, Verona, Italy.

Gabriele Capurso (G)

Digestive and Liver Disease Unit, S. Andrea Hospital, University Sapienza, Rome, Italy.

Giulia Martina Cavestro (GM)

Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Ospedale San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Giovanni Butturini (G)

Pancreatic Surgery Unit, Casa di Cura Pederzoli Hospital, Peschiera del Garda, Italy.

Raffaele Pezzilli (R)

Internal Medicine, University of Bologna, Bologna, Italy.

Roberto Salvia (R)

General and Pancreatic Surgery Department, Pancreas Institute, University of Verona, Verona, Italy.

Marianna Signoretti (M)

Digestive and Liver Disease Unit, S. Andrea Hospital, University Sapienza, Rome, Italy.

Stefano Crippa (S)

Pancreatic Surgery Unit, IRCCS Ospedale San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milano, Italy.

Silvia Carrara (S)

Gastrointestinal Endoscopy, Istituto Clinico Humanitas, Milano, Italy.

Isabella Frigerio (I)

Pancreatic Surgery Unit, Casa di Cura Pederzoli Hospital, Peschiera del Garda, Italy.

Claudio Bassi (C)

General and Pancreatic Surgery Department, Pancreas Institute, University of Verona, Verona, Italy.

Massimo Falconi (M)

Pancreatic Surgery Unit, IRCCS Ospedale San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milano, Italy.

Elsa Iannicelli (E)

Radiology Unit, S. Andrea Hospital, University Sapienza, Rome, Italy.

Alessandro Giardino (A)

Pancreatic Surgery Unit, Casa di Cura Pederzoli Hospital, Peschiera del Garda, Italy.

Alessandro Mannucci (A)

Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Ospedale San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Andrea Laghi (A)

Radiology Unit, S. Andrea Hospital, University Sapienza, Rome, Italy.

Luigi Laghi (L)

Hereditary Cancer Genetics Clinic, Humanitas Clinical and Research Center, Milano, Italy.

Luca Frulloni (L)

Gastroenterology B Unit, Pancreas Institute, University of Verona, Verona, Italy.

Alessandro Zerbi (A)

Pancreatic Surgery Unit, Humanitas Clinical and Research Center, Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH